Advertisement

Topics

FDA grants Xtandi priority review for Nonmetastatic CRPC

04:02 EDT 20 Mar 2018 | Pharmaceutical Business Review

The US Food and Drug Administration (FDA) has accepted Pfizer and Astellas Pharma's supplemental New Drug Application (sNDA) for Xtandi (enzalutamide) for a new indication and granted priority review designation.

Original Article: FDA grants Xtandi priority review for Nonmetastatic CRPC

NEXT ARTICLE

More From BioPortfolio on "FDA grants Xtandi priority review for Nonmetastatic CRPC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...